2026 Eastern States Conference

Feasibility and impact of an area under the curve-guided dosing protocol of aminoglycosides using Bayesian modeling software among adult and pediatric hospitalized patients
Authors: Madeiline Osborn, PharmD; Craig Worby, PharmD; Rebecca Wang, MD; Jeffrey Low, PharmD; Julie Ann Justo, PharmD, MS
Learning Objective: Understand the benefits of AUC-guided aminoglycoside dosing compared with traditional dosing methods.
Objective: The primary objective is to assess feasibility of AUC-guided dosing compared with prior methods, as measured by pharmacist-reported surveys. Secondary objectives include comparing clinical outcomes before and after implementation.
Methods: This study, using a mixed-methods design, is a retrospective, observational cohort study of hospitalized adult and pediatric patients treated with aminoglycosides between November 2024 and June 2026, with pharmacist surveys to assess feasibility of these processes administered pre- and post-implementation. Survey responses will be summarized using descriptive statistics, and pre- and post-implementation results will be compared to evaluate changes in feasibility, ease of use, and satisfaction.
Results: Results are pending as the study is being conducted.
Conclusions: This study is expected to clarify the feasibility and clinical impact of implementing AUC-guided aminoglycoside dosing at a tertiary medical center, informing antimicrobial stewardship and institutional policy.
Self-Assessment Question: 
True or False: AUC-guided dosing provides a pharmacokinetic approach that measures total drug exposure over time and may offer a more accurate method for optimizing aminoglycoside therapy